Paloma Partners’s Novavax NVAX Stock Holding History

Paloma Partners’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-3,800	Closed	-$412K	–	2059
2020 Q3	$412K	Buy	+3,800	New	+$463K	0.01%	1294

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Paloma Partners's NVAX Position: Q4 2020 in Review

Paloma Partners sold out of Novavax (NVAX) in Q4 2020, closing a stake of 1,991 shares — an estimated $216K sold.

Paloma Partners first reported a position in NVAX in Q3 2014 and held it in 9 quarters. The position peaked at $339K in Q3 2015. 347 funds tracked by Wall St. Rank hold NVAX as of Q4 2020.

Paloma Partners reported no remaining Novavax position as of Q4 2020 after selling out during the quarter.
Paloma Partners sold 1,991 Novavax shares in Q4 2020, an estimated $216K.
Paloma Partners first reported a position in Novavax in Q3 2014 and held it in 9 quarters.
Paloma Partners's Novavax position peaked at $339K in Q3 2015.
347 funds tracked by Wall St. Rank held Novavax as of Q4 2020.

Based on Paloma Partners's 13F filing for Q4 2020, filed 16 Feb 2021.